NCT05232162

Brief Summary

Elevated aldosterone levels were also shown to contribute to the excess morbidity and mortality. Literature shows aldosterone and renin levels differ between ethnicity and gender. There is no established reference intervals for these two hormone levels in Asian community. We aim to establish reference intervals for plasma aldosterone and direct renin concentrations among Malaysians residing in Sarawak using the chemiluminescent immunoassay (CLIA). This is a cross-sectional study which will be conducted among ambulatory patients, healthy blood donors and healthy volunteers. 300 participants who fulfil study criteria will be recruited after informed consent. Socio-demographic data and anthropometric measurements will be recorded. Blood will be taken for plasma aldosterone, renin, serum potassium and creatinine. Urine will be collected for estimation of 24-hour sodium excretion. Aldosterone and renin reference intervals will be established partitioned for gender.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 15, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 30, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 9, 2022

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

February 9, 2022

Status Verified

January 1, 2022

Enrollment Period

2 years

First QC Date

January 30, 2022

Last Update Submit

January 30, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Aldosterone and renin reference intervals

    24 months

Secondary Outcomes (1)

  • Aldosterone and renin reference intervals partitioned for gender

    24 months

Eligibility Criteria

Age18 Years+
Sexall(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Ambulatory healthy volunteers

You may qualify if:

  • aged 18 years old and above
  • agreeable to participate in this study
  • normal kidney function (eGFR\>60ml/min/1.73m2)
  • Malaysian
  • BMI\<27.5kg/m2

You may not qualify if:

  • taking prescribed/OTC medications within 3 months of study
  • taking estrogen, either in oral contraceptive pills or hormone replacement therapy
  • having hypertension defined as blood pressure\>140/90mmHg or on anti-hypertensive
  • having hypokalemia (serum potassium \<3.5mmol/L)
  • pregnant
  • smoker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universiti Malaysia Sarawak

Kuching, Sarawak, 93350, Malaysia

RECRUITING

MeSH Terms

Conditions

Hyperaldosteronism

Condition Hierarchy (Ancestors)

Adrenocortical HyperfunctionAdrenal Gland DiseasesEndocrine System Diseases

Central Study Contacts

Huai Heng H Loh

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 30, 2022

First Posted

February 9, 2022

Study Start

December 15, 2021

Primary Completion

December 1, 2023

Study Completion

December 1, 2023

Last Updated

February 9, 2022

Record last verified: 2022-01

Data Sharing

IPD Sharing
Will not share

Locations